Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia.
Hayashi, Y; Goyama, S; Liu, X; Tamura, M; Asada, S; Tanaka, Y; Fukuyama, T; Wunderlich, M; O'Brien, E; Mizukawa, B; et al.
Nature Communications.
2019;
10.
Improved chemotherapy modeling with RAG-based immune deficient mice.
Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O’Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC.
PLoS ONE.
2019;
14:e0225532-e0225532.
Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis.
Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al.
Pediatric Blood and Cancer.
2018;
65:e27400-e27400.
A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells.
Du, W; Liu, W; Mizukawa, B; Shang, X; Sipple, J; Wunderlich, M; Geiger, H; Davies, S; Mulloy, J; Pang, Q; et al.
Leukemia.
2018;
32:2041-2046.
Cell polarity and division symmetry analyses in transformed blood cells.
Mizukawa, B; O'Brien, E; Mulloy, JC; Zheng, Y.
Methods in molecular biology (Clifton, N.J.).
2018;
1821:257-266.
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth, L; O'Donohue, T; Chen, Z; Bartlett, NL; LaCasce, A; Martin-Doyle, W; Barth, MJ; Davies, K; Blum, KA; Christian, B; et al.
British Journal of Haematology.
2017;
179:739-747.
The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
Mizukawa, B; O'Brien, E; Moreira, DC; Wunderlich, M; Hochstetler, CL; Duan, X; Liu, W; Orr, E; Grimes, HL; Mulloy, JC; et al.
Blood.
2017;
130:1336-1346.
Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.
Goyama, S; Shrestha, M; Schibler, J; Rosenfeldt, L; Miller, W; O'Brien, E; Mizukawa, B; Kitamura, T; Palumbo, JS; Mulloy, JC.
Oncogene: Including Oncogene Reviews.
2017;
36:2589-2598.
A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.
Wunderlich, M; Stockman, C; Devarajan, M; Ravishankar, N; Sexton, C; Kumar, AR; Mizukawa, B; Mulloy, JC.
JCI insight.
2016;
1.
Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.
Glait-Santar, C; Desmond, R; Feng, X; Bat, T; Chen, J; Heuston, E; Mizukawa, B; Mulloy, JC; Bodine, DM; Larochelle, A; et al.
Stem Cells.
2015;
33:3635-3642.